This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS
by Zacks Equity Research
Glaukos (GKOS) announces the receipt of a permanent J-code for iDose TR from the CMS, which is likely to boost the billing and payment process.
Reasons to Add Cardinal Health (CAH) to Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now
by Zacks Equity Research
Ecolab's (ECL) focus on research and development raises optimism about the stock.
Cencora, Inc. (COR) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Veeva Systems (VEEV) Makes Change to Front Office (revised)
by Zacks Equity Research
Veeva Systems' (VEEV) CFO Brent Bowman steps down, leading analysts to weigh in on the impact and prospects for the cloud-solutions company.
Quest Diagnostics (DGX) Collaborates With Broad Clinical Labs
by Zacks Equity Research
Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.
QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing
by Zacks Equity Research
QuidelOrtho (QDEL) announces the FDA's approval of QuickVue, which is likely to be used for convenient and accurate COVID-19 pathogen testing.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Veeva Systems' (VEEV) CFO Resignation Sparks 6% Stock Drop
by Zacks Equity Research
Veeva Systems' (VEEV) CFO, Brent Bowman, steps down, causing a 6% stock price decline. Analysts weigh in on the impact and prospects for the cloud-solutions company.
Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy
by Zacks Equity Research
Baxter's (BAX) Novum IQ Infusion Platform is likely to help enhance patient safety and efficiency for clinicians following the FDA's clearance.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.
Abbott's (ABT) i-STAT TBI Cartridge Receives FDA Approval
by Zacks Equity Research
Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion.
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Three Reasons to Retain Revvity (RVTY) Stock in Your Portfolio
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
Here's Why Investors Should Buy ResMed (RMD) Stock Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) led by the strong uptake of the myAir app with Air 11 systems.
Labcorp (LH) to Boost Clinical Diagnostics With New Deal
by Zacks Equity Research
The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
by Zacks Equity Research
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.
Here's Why Cencora (COR) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Investors Should Hold Teladoc (TDOC) Stock Now
by Zacks Equity Research
Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Walgreens Boots (WBA) Q2 Earnings Top Estimates, EPS View Down
by Zacks Equity Research
Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal second quarter benefited from higher branded drug inflation and strong execution in pharmacy services.
GE HealthCare's (GEHC) PVA to Aid in Capturing Prostate Volume
by Zacks Equity Research
GE HealthCare (GEHC) announces the launch of Prostate Volume Assist AI-enabled urology software feature, which is likely to boost prostate imaging, capture prostate volume and increase workflow.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.